141 related articles for article (PubMed ID: 2171940)
1. In vitro activity of saperconazole (R66 905) compared with amphotericin B and itraconazole against Aspergillus species.
Denning DW; Hanson LH; Stevens DA
Eur J Clin Microbiol Infect Dis; 1990 Sep; 9(9):693-7. PubMed ID: 2171940
[TBL] [Abstract][Full Text] [Related]
2. In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents.
Denning DW; Hanson LH; Perlman AM; Stevens DA
Diagn Microbiol Infect Dis; 1992 Jan; 15(1):21-34. PubMed ID: 1309690
[TBL] [Abstract][Full Text] [Related]
3. Comparison of azoles against aspergilli in vitro and in an experimental model of pulmonary aspergillosis.
Schmitt HJ; Edwards F; Andrade J; Niki Y; Armstrong D
Chemotherapy; 1992; 38(2):118-26. PubMed ID: 1317280
[TBL] [Abstract][Full Text] [Related]
4. Effect of increasing inoculum sizes of Aspergillus hyphae on MICs and MFCs of antifungal agents by broth microdilution method.
Lass-Flörl C; Speth C; Kofler G; Dierch MP; Gunsilius E; Würzner R
Int J Antimicrob Agents; 2003 Mar; 21(3):229-33. PubMed ID: 12636983
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy of amphotericin B, clotrimazole and itraconazole against Aspergillus spp. An in vitro study.
Hahn YH; Ahearn DG; Wilson LA
Mycopathologia; 1993 Sep; 123(3):135-40. PubMed ID: 8302362
[TBL] [Abstract][Full Text] [Related]
6. Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following treatment with amphotericin B.
Paterson PJ; Seaton S; Prentice HG; Kibbler CC
J Antimicrob Chemother; 2003 Nov; 52(5):873-6. PubMed ID: 14519673
[TBL] [Abstract][Full Text] [Related]
7. In Vitro Interactions between Target of Rapamycin Kinase Inhibitor and Antifungal Agents against Aspergillus Species.
Gao L; Ding X; Liu Z; Wu Q; Zeng T; Sun Y
Antimicrob Agents Chemother; 2016 Jun; 60(6):3813-6. PubMed ID: 26976874
[TBL] [Abstract][Full Text] [Related]
8. MIC and fungicidal activity of terbinafine against clinical isolates of Aspergillus spp.
Schmitt HJ; Bernard EM; Andrade J; Edwards F; Schmitt B; Armstrong D
Antimicrob Agents Chemother; 1988 May; 32(5):780-1. PubMed ID: 3134851
[TBL] [Abstract][Full Text] [Related]
9. In-vitro activity of the new triazole D0870 compared with amphotericin B and itraconazole against Aspergillus spp.
Moore CB; Law D; Denning DW
J Antimicrob Chemother; 1993 Dec; 32(6):831-6. PubMed ID: 8144422
[TBL] [Abstract][Full Text] [Related]
10. In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates.
Verweij PE; Mensink M; Rijs AJ; Donnelly JP; Meis JF; Denning DW
J Antimicrob Chemother; 1998 Sep; 42(3):389-92. PubMed ID: 9786480
[TBL] [Abstract][Full Text] [Related]
11. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592).
Manavathu EK; Cutright JL; Loebenberg D; Chandrasekar PH
J Antimicrob Chemother; 2000 Aug; 46(2):229-34. PubMed ID: 10933645
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus.
Cuenca-Estrella M; Rodríguez-Tudela JL; Mellado E; Martínez-Suárez JV; Monzón A
J Antimicrob Chemother; 1998 Oct; 42(4):531-3. PubMed ID: 9818755
[TBL] [Abstract][Full Text] [Related]
13. In-vitro susceptibility of Aspergillus spp. isolates to amphotericin B and itraconazole.
Dannaoui E; Persat F; Monier MF; Borel E; Piens MA; Picot S
J Antimicrob Chemother; 1999 Oct; 44(4):553-5. PubMed ID: 10588320
[TBL] [Abstract][Full Text] [Related]
14. Effect of increasing inoculum sizes of pathogenic filamentous fungi on MICs of antifungal agents by broth microdilution method.
Gehrt A; Peter J; Pizzo PA; Walsh TJ
J Clin Microbiol; 1995 May; 33(5):1302-7. PubMed ID: 7615745
[TBL] [Abstract][Full Text] [Related]
15. In vitro activities of amphotericin B in combination with four antifungal agents and rifampin against Aspergillus spp.
Hughes CE; Harris C; Moody JA; Peterson LR; Gerding DN
Antimicrob Agents Chemother; 1984 May; 25(5):560-2. PubMed ID: 6329088
[TBL] [Abstract][Full Text] [Related]
16. In vitro antifungal susceptibility of clinical and environmental isolates of Aspergillus fumigatus and Aspergillus flavus in Brazil.
Bedin Denardi L; Hoch Dalla-Lana B; Pantella Kunz de Jesus F; Bittencourt Severo C; Morais Santurio J; Zanette RA; Hartz Alves S
Braz J Infect Dis; 2018; 22(1):30-36. PubMed ID: 29172033
[TBL] [Abstract][Full Text] [Related]
17. Single-dose pharmacodynamics of amphotericin B against Aspergillus species in an in vitro pharmacokinetic/pharmacodynamic model.
Al-Saigh R; Siopi M; Siafakas N; Velegraki A; Zerva L; Meletiadis J
Antimicrob Agents Chemother; 2013 Aug; 57(8):3713-8. PubMed ID: 23716054
[TBL] [Abstract][Full Text] [Related]
18. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp.
Oakley KL; Moore CB; Denning DW
Antimicrob Agents Chemother; 1998 Oct; 42(10):2726-30. PubMed ID: 9756785
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Sensititre YeastOne with the NCCLS M38-A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus.
Guinea J; Peláez T; Alcalá L; Bouza E
Diagn Microbiol Infect Dis; 2006 Sep; 56(1):53-5. PubMed ID: 16650953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
